Коллектив авторов, 2014
... Criteria of inclusion were: age from 18 to 70 years; newly detected microbiologically proven tuberculosis of respiratory apparatus, presence of MDR-MTB determined using molecular genetic methods of analysis (MGA), and mutations associated with resistance at least to R or R and H. Criteria of exclusi ...
... Criteria of inclusion were: age from 18 to 70 years; newly detected microbiologically proven tuberculosis of respiratory apparatus, presence of MDR-MTB determined using molecular genetic methods of analysis (MGA), and mutations associated with resistance at least to R or R and H. Criteria of exclusi ...
Efficacy and safety of a 12-week course of therapy with a new
... researcher, may disrupt participation in the study. 11. Hypersensitivity or allergy to the drugs used in the study. 12. Diabetes. 13. Irregular PEF measurements and taking of the studied drugs (more than 20% of measurements omitted or doses of the studied drug not taken). 14. The use of systemic ste ...
... researcher, may disrupt participation in the study. 11. Hypersensitivity or allergy to the drugs used in the study. 12. Diabetes. 13. Irregular PEF measurements and taking of the studied drugs (more than 20% of measurements omitted or doses of the studied drug not taken). 14. The use of systemic ste ...
Role of Novel Drug Delivery Systems in
... drug delivery systems by transport the drug to the place of systemic circulation, thereby accessing the site of action. action, hence, its influence on vital tissues and undesirable side effects can be minimized so the accumulation of The NDDS like liposomes, niosomes, bilosomes, therapeutic compoun ...
... drug delivery systems by transport the drug to the place of systemic circulation, thereby accessing the site of action. action, hence, its influence on vital tissues and undesirable side effects can be minimized so the accumulation of The NDDS like liposomes, niosomes, bilosomes, therapeutic compoun ...
Statins - Consumer Health Choices
... This series is produced by Consumer Reports and Consumer Reports Best Buy Drugs, a public information project supported by grants from the Engelberg Foundation and the National Library of Medicine of the National Institutes of Health. These materials were also made possible by a grant from the State ...
... This series is produced by Consumer Reports and Consumer Reports Best Buy Drugs, a public information project supported by grants from the Engelberg Foundation and the National Library of Medicine of the National Institutes of Health. These materials were also made possible by a grant from the State ...
Review of Principles - LSU School of Medicine
... initiates a cellular response; has affinity and efficacy. Agonists promote the active state. Antagonist: drug that binds to receptors but cannot initiate a cellular response, but prevent agonists from producing a response; affinity, but no efficacy. Antagonists maintain the active-inactive equilibri ...
... initiates a cellular response; has affinity and efficacy. Agonists promote the active state. Antagonist: drug that binds to receptors but cannot initiate a cellular response, but prevent agonists from producing a response; affinity, but no efficacy. Antagonists maintain the active-inactive equilibri ...
cardiopulmonary resuscitation - Cornell University Veterinary
... ETCO2 increases dramatically, and can therefore be useful as early indicator of ROSC Pharmacotherapy is an important aspect of advanced life support. Vasopressors are used for patients with asystole, PEA, and persistent vfib. Epinephrine is a catecholamine, and has potent α1, β1, and β2 effects. The ...
... ETCO2 increases dramatically, and can therefore be useful as early indicator of ROSC Pharmacotherapy is an important aspect of advanced life support. Vasopressors are used for patients with asystole, PEA, and persistent vfib. Epinephrine is a catecholamine, and has potent α1, β1, and β2 effects. The ...
Non Compartmental Pharmacokinetics
... concentration on repetitive dosing from data obtained after a single dose. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU ...
... concentration on repetitive dosing from data obtained after a single dose. Ch.Karthik SivaChaitanya,M.Pharm 1st Sem,UCPSc,KU ...
Migraine - Bradford VTS
... Migraine patients are defined as individuals who have had at least 2 attacks with aura or 5 attacks without aura. Women are 2-3 times more likely to suffer from migraine. 10% of the general population are active migraineurs ( 6% males and 15% females ). First peak around 14-16ys with a second less a ...
... Migraine patients are defined as individuals who have had at least 2 attacks with aura or 5 attacks without aura. Women are 2-3 times more likely to suffer from migraine. 10% of the general population are active migraineurs ( 6% males and 15% females ). First peak around 14-16ys with a second less a ...
Academic paper: A Diarylquinoline Drug Active on the ATP
... proton pump of adenosine triphosphate (ATP) synthase. After AIDS, tuberculosis (TB) is the leading cause of infectious disease mortality in the world, with 2 million to 3 million deaths per year (1). The TB and HIV epidemics fuel one another in coinfected people, and at least 11 million adults are i ...
... proton pump of adenosine triphosphate (ATP) synthase. After AIDS, tuberculosis (TB) is the leading cause of infectious disease mortality in the world, with 2 million to 3 million deaths per year (1). The TB and HIV epidemics fuel one another in coinfected people, and at least 11 million adults are i ...
Slide 1 - The Ophthalmology Report 2013
... groups in terms of the number of eyes that lost or gained 15 letters of visual acuity. » Patients randomized to as-needed treatment with bevacizumab received more injections (mean, 7.7) than did those given as-needed ranibizumab (mean, 6.9). ...
... groups in terms of the number of eyes that lost or gained 15 letters of visual acuity. » Patients randomized to as-needed treatment with bevacizumab received more injections (mean, 7.7) than did those given as-needed ranibizumab (mean, 6.9). ...
Unit- 2 - Shree Medical and Technical College
... 1.5. Techniques in estimation of enzymes and endogenous substances in body fluids in physiological and pathological conditions. 1.6. Department of Drug Administration, (DDA) Nepal and Indian requirements (Schedule T) and other regulatory requirements for the manufacturing of Herbal and Ayurvedic pro ...
... 1.5. Techniques in estimation of enzymes and endogenous substances in body fluids in physiological and pathological conditions. 1.6. Department of Drug Administration, (DDA) Nepal and Indian requirements (Schedule T) and other regulatory requirements for the manufacturing of Herbal and Ayurvedic pro ...
View - SciTechnol
... continued for approximately 4–6 hours. The patient reported that TP was more effective than SB. IES-R and CAPS evaluations confirmed the improvements in FBs after TP administration. As shown in Table 1, her IES-R scores were 81 and 37 before and after TP administration, respectively. The CAPS score ...
... continued for approximately 4–6 hours. The patient reported that TP was more effective than SB. IES-R and CAPS evaluations confirmed the improvements in FBs after TP administration. As shown in Table 1, her IES-R scores were 81 and 37 before and after TP administration, respectively. The CAPS score ...
the publication - Oncovet Clinical Research
... initiated in refractory/relapsing acute myeloid leukemia (AML). Promising antileukemic activity was observed at different dose levels (12) and F14512 is currently in a phase I/II trial in AML in combination with cytarabine. Preclinical data showed that lymphoma could be an indication of interest for ...
... initiated in refractory/relapsing acute myeloid leukemia (AML). Promising antileukemic activity was observed at different dose levels (12) and F14512 is currently in a phase I/II trial in AML in combination with cytarabine. Preclinical data showed that lymphoma could be an indication of interest for ...
U4C3L1 - lecjrotc
... these ill effects reaches new heights, more and more Americans are joining forces to fight alcohol abuse everyday. When a person drinks alcohol, it follows the same pathway as food through the digestive system. Unlike food, however, alcohol does not have to be digested by the stomach to be absorbed ...
... these ill effects reaches new heights, more and more Americans are joining forces to fight alcohol abuse everyday. When a person drinks alcohol, it follows the same pathway as food through the digestive system. Unlike food, however, alcohol does not have to be digested by the stomach to be absorbed ...
Report of the Psychiatric Drug Safety Expert Advisory Panel
... The reports contained details of the experiences of several healthcare professionals involved in the management of patients who had received a variety of psychiatric medicines and experienced adverse events. In correspondence the psychiatrist had raised particular concerns over the safety of selecti ...
... The reports contained details of the experiences of several healthcare professionals involved in the management of patients who had received a variety of psychiatric medicines and experienced adverse events. In correspondence the psychiatrist had raised particular concerns over the safety of selecti ...
Appendix S5.
... other hand, the mode of action of this class of compounds seems to make it plausible that nematodes in general would be susceptible to the action of monepantel. Notwithstanding these claims of efficacy against human pathogens, monepantel was first developed as a veterinary drug, most probably becaus ...
... other hand, the mode of action of this class of compounds seems to make it plausible that nematodes in general would be susceptible to the action of monepantel. Notwithstanding these claims of efficacy against human pathogens, monepantel was first developed as a veterinary drug, most probably becaus ...
Rethinking and Restructuring the FDA Drug Approval Process in
... Gastrointestinal Outcomes Research (VIGOR), sponsored by Merck, and Celecoxib Long-term Arthritis Safety Study (CLASS), sponsored by Pfizer. The paper also analyzed two smaller studies, including Study 090, which Merck sponsored but never published. Although the VIGOR study was designed to measure t ...
... Gastrointestinal Outcomes Research (VIGOR), sponsored by Merck, and Celecoxib Long-term Arthritis Safety Study (CLASS), sponsored by Pfizer. The paper also analyzed two smaller studies, including Study 090, which Merck sponsored but never published. Although the VIGOR study was designed to measure t ...
Anatomy of an In-Custody Death—Medical Causation Issues
... behavior. At that time, there was lack of effective pharmacologic treatment available for these patients. The behavior seen in these cases has been called ‘‘Bell’s Mania,’’ named after Dr. Luther Bell, the primary psychiatrist at the McLean Asylum for the Insane in Massachusetts. Dr. Bell was the fi ...
... behavior. At that time, there was lack of effective pharmacologic treatment available for these patients. The behavior seen in these cases has been called ‘‘Bell’s Mania,’’ named after Dr. Luther Bell, the primary psychiatrist at the McLean Asylum for the Insane in Massachusetts. Dr. Bell was the fi ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... beclomethazone.fluticasone and budsunide. Thereis no significant association between type of treatment and Tscore. This may attributed to small size sample of asthmatic patients which agreed with Boulet et al (21) studied of 37 asthmatic patients who had using 800 µg\ day or greater of beclornethaso ...
... beclomethazone.fluticasone and budsunide. Thereis no significant association between type of treatment and Tscore. This may attributed to small size sample of asthmatic patients which agreed with Boulet et al (21) studied of 37 asthmatic patients who had using 800 µg\ day or greater of beclornethaso ...
LEADS PHARMA
... Leads Pharma has been in the forefront since a decade exporting a number of variants of Sheath Contraceptives (Condoms) to the Middle East Countries under the brand name of INVIGRA manufactured at a US FDA approved facility. After seeing the success of the product INVIGRA Leads ventured into marketi ...
... Leads Pharma has been in the forefront since a decade exporting a number of variants of Sheath Contraceptives (Condoms) to the Middle East Countries under the brand name of INVIGRA manufactured at a US FDA approved facility. After seeing the success of the product INVIGRA Leads ventured into marketi ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.